Back to home » Top Stories » IAC 2010
XVIII International AIDS Conference
IAC 2010 XVIII International AIDS Conference
Reed Messe Wien
Vienna, Austria
July 18-23, 2010


HIV/HCV Coinfection Further Increases Risk of Bone Fractures

July 20, 2010

By Tim Horn

Compared with people living with HIV, people coinfected with HIV and hepatitis C virus (HCV) appear to face an even higher risk of bone fractures, according to new data reported Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.

Decreased bone mineral density is increasingly reported in the aging HIV-positive population, explained Roger Bedimo, MD, of the VA North Texas Health Care System in his introductory remarks. The risk of fractures has also been found to be increased among people living with HIV, compared with non-HIV-infected patients.

The overall prevalence of fragility fractures—a broken vertebrae, hip or wrist after falling from standing height or less—is higher among women, but men face a greater risk of death associated with fractures and they account for the majority of HIV cases in the United States. According to Bedimo, the overall mortality is about 20 percent in the first 12 months after a hip fracture and is higher in men than women.

Bedimo also noted that 15 to 30 percent of people living with HIV are coinfected with HCV, which by itself is associated with osteoporosis.

To determine whether or not HCV coinfection adds to the risk of osteoporotic fractures among people living with HIV, Bedimo and his colleagues analyzed data from the Veterans Affairs’ Clinical Case Registry. Included in the analysis were patient data collected before the widespread use of combination ARV therapy (1988 to 1995) and the contemporary era of combination treatment (1996 to 2009).

More than 56,500 patients were included in the analysis; 98 percent were male, and about a third were HIV/HCV coinfected. The average age at entry was 45.

Patients were followed in the cohort for an average of 5.4 years. About 64 percent of those included in the analysis had been on antiretroviral therapy for at least one month, with an average treatment duration of four years.

According to the analysis, 951 patients sustained at least one osteoporotic fracture, including 106 vertebral factures, 451 wrist fractures and 308 hip fractures. The rate, per 1,000 patient-years of follow-up, was 2.54 among those only infected with HIV, compared with 3.25 among those coinfected with HIV and HCV.

Several known osteoporotic risk factors were echoed in the VA study, including older age, white race, tobacco use, diabetes and a low body mass index (less than 20). Bedimo also reported that while people with HCV coinfection only made up 31.2 percent of the study population, they accounted for more than 50 percent of the reported osteoporotic fractures.   

Looking only at data collected between 1996 and 2006, the fracture rate—per 1,000 patient-years—was 2.86 among those with HIV monoinfection, compared with 4.06 among those with HIV/HCV coinfection. During the entire study period—1988 through 2009—the fracture rates were 2.54 and 3.35, respectively.

In conclusion, Bedimo reiterated that HCV coinfection is associated with a higher risk of osteoporotic fractures among people living with HIV. He added that the risk of osteoporotic fractures appears to be increasing in the modern-day treatment era among HIV/HCV-coinfected patients.

Bedimo also noted that, contrary to increasing rates of osteoporotic fractures in recent years, exposure to ARV therapy may be protective against bone breaks.  The lower rates of fractures in the pre-combination ARV therapy era can likely be chalked up to premature death due to AIDS-related illnesses, which ultimately occurred before an osteoporotic fracture could be documented. Then again, he said, combination ARV therapy might not be protective, adding that a VA analysis exploring the positive—or potentially negative—effects of modern-day HIV treatment on osteoporotic fracture risk is in progress.

Search: hepatitis C, HCV, osteoporosis, bone mineral density, fracture, hip, wrist, vertebrae, bone, Vienna, International AIDS Conference, Bedimo

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

More from AIDS2010

HIV/AIDS Complications

July 28, 2010
Global Survey: Stigma, Isolation and Discrimination Still Pervasive
Universal HIV Treatment Access No Guarantee of Health for Socially Disadvantaged
July 27, 2010
OM-85 BV: A Bacterial Vaccine Against Respiratory Problems in People with HIV and COPD?
Low Vitamin D Levels Not Associated With HIV Drugs
July 23, 2010
Longer Duration of HIV Infection Might Increase the Risk of Brain Disorders
Nearly 75 Percent of People With HIV Might Have Bone Problems
July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 21, 2010
Non-AIDS Cancers Occurring at Earlier Age Among People With HIV
Hep C Treatment Effective in HIV Patients With Normal Liver Enzymes
Aging Might Have a Smaller Impact on Immune Function Than Suspected
July 20, 2010
Viramune Boosts Hep C Treatment Efficacy in People With HIV
HIV/HCV Coinfection Further Increases Risk of Bone Fractures
Fewer Malignancies Seen in Those Taking Selzentry

Experimental HIV Drugs

July 23, 2010
More Details of TBR-652’s Antiviral and Anti-Inflammatory Potential Reported
July 22, 2010
ViiV HIV Integrase Inhibitor Performing Well in First-Time Treatment Study
Rilpivirine Has Similar Efficacy and Better Tolerability Than Sustiva
Extended-Release Viramune Has Comparable Safety and Efficacy to Standard Viramune
July 20, 2010
New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains
July 19, 2010
Argos’s Dendritic Cell Therapy Reduces HIV During Treatment Interruption

HIV Transmission and Prevention

July 29, 2010
Prevention Is Failing to Target MSM When They’re Young Enough
July 26, 2010
HPV Cancer Vaccine Effective for Heterosexual, Gay and Bisexual Men
Study Finds PrEP Is Safe in Gay and Bi Men
July 23, 2010
Circumcision Unlikely to Have Major HIV Prevention Benefit Among Gay Men
July 21, 2010
Microbicide Success Story: What It Means and Where We Go Next
MACS: Childhood Sex Abuse and Victimization Linked to Increased HIV Risk
Full-Scale HIV Treatment and Prevention Could Save Millions of Lives
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
HIV Cases in Young People Are Falling Around the World
July 19, 2010
Preliminary Results Suggest Good Safety and Adherence Profile for PrEP

Starting and Switching Treatment

July 22, 2010
Reyataz/Isentress Combo Spares Norvir and Nukes, But Is Integrase Resistance a Concern?
Possibly No Survival Benefit to Starting HIV Treatment at CD4s of 500 or More
Once-Daily Prezista/Norvir Monotherapy Largely Effective Over 96 Weeks
Abacavir/Lamivudine Equivalent to Tenofovir/Emtricitabine in Canadian Cohort Study
July 19, 2010
Strategies for a Cure Reviewed in Vienna
Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects
Protease Inhibitor-to-Isentress Switch is Effective, Lipid Friendly


July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment
At Least 31 Countries Deporting People Living With HIV
HIV Cases in Young People Are Falling Around the World

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.